QQQ
+ 5.65
360.84
+ 1.54%
BTC/USD
+ 1643.46
43303.47
+ 3.94%
DIA
+ 4.07
346.28
+ 1.16%
SPY
+ 5.76
445.99
+ 1.28%
TLT
+ 0.09
140.98
+ 0.06%
GLD
-0.10
172.18
-0.06%

Qiagen Says Its COVID-19 PCR Tests Can Detect The New South African Variant

November 26, 2021 11:01 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Qiagen Says Its COVID-19 PCR Tests Can Detect The New South African Variant

Qiagen N.V. (NYSE:QGEN) announced that its polymerase chain reaction (PCR) tests remain accurate and effective in detecting COVID-19 infections in light of the emergence of a new variant detected in South Africa.

  • Qiagen has assessed its COVID-19 PCR tests against the genetic mutations of the variant, dubbed B.1.1.529. 
  • The assessment was made against data available in the GISAID and GenBank public databases.
  • It applies to all of Qiagen's PCR tests for detection of the SARS-CoV-2 virus involving:
  • Artus SARS-CoV-2 Prep&Amp UM Kit, a test that integrates sample preparation and detection in a single kit, enabling a throughput of over 670 tests per PCR cycler in an eight-hour shift
  • QIAstat-Dx syndromic testing system, which includes QIAstat-Dx Respiratory 4 Plex Flu A-B/RSV/SARS-CoV-2 to identify in about an hour whether patients have common seasonal respiratory infections or SARS-CoV-2.
  • NeuMoDx 96 and 288 integrated PCR testing systems used in laboratory testing.
  • Furthermore, the new variant is reliably detected by QIAcuity digital PCR and QIAprep&amp Viral RNA kit.
  • Price Action: QGEN shares are up 4.53% at $57.03 during the market session on the last check Friday.

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to Benzinga Podcasts and our YouTube channel.


Related Articles

Qiagen Stock gains As Non COVID Sales Boosts Q2 Topline, Bottom-line

Qiagen Stock gains As Non COVID Sales Boosts Q2 Topline, Bottom-line

PreMarket Prep Recap: Qiagen Pulls The Rug Out From Investors Banking On A Deal, Bad Data Equals Bad Price Action For Spectrum Pharmaceuticals

PreMarket Prep Recap: Qiagen Pulls The Rug Out From Investors Banking On A Deal, Bad Data Equals Bad Price Action For Spectrum Pharmaceuticals

Stocks to Watch for Wednesday 8/03/2011: Fresh 52 Week Highs and Lows

Stocks to Watch for Tuesday 8/02/2011: Fresh 52-Week Highs and Lows